使用基于CT的评分量表评估局部晚期甲状腺癌的病变范围和可切除性
这项双中心回顾性研究纳入95例局部晚期甲状腺癌患者作为训练队列、31例作为测试队列,由三名放射科医生对喉返神经、气管、食管、动脉、静脉、软组织和喉受累进行CT评分,建立14分和12分量表。12分量表(排除喉)的AUC为0.882,不劣于14分量表(AUC=0.891),外部验证AUC为0.875。
要点
- 12分CT量表(含喉返神经、气管、食管、动脉、静脉、软组织)可用于评估局部晚期甲状腺癌可切除性。
- 喉受累不是不可切除的预测因素(p=0.283),故12分量表排除喉。
- 12分量表在训练队列AUC=0.882,外部验证AUC=0.875。
核心结论
- 研究者建立了基于CT的12分量表用于评估局部晚期甲状腺癌的可切除性,但需要更大样本量验证其效能。
研究设计与样本
- 双中心回顾性研究,训练队列95例(第1中心),测试队列31例(第2中心),三名放射科医生对CT扫描进行评分,以可切除与不可切除分组,采用ROC分析、分层五折交叉验证和外部验证。
关键影像表现/征象
- 训练队列中,喉返神经(p<0.001)、气管(p=0.001)、食管(p=0.002)、动脉(p<0.001)、静脉(p=0.005)和软组织(p<0.001)受累是不可切除的预测因素。
- 喉受累不是不可切除的预测因素(p=0.283)。
诊断标准与关键数值
- 12分量表(排除喉)AUC=0.882(95%CI:0.812-0.952),不劣于14分量表AUC=0.891(95%CI:0.823-0.960)。
- 亚组分析:12分量表在初治患者中AUC=0.826,在有手术史患者中AUC=0.976。
- 五折交叉验证总体准确率为78.9%-89.4%。
- 外部验证(测试队列)AUC=0.875。
临床应用与阅片要点
- 该12分CT量表可能帮助临床医生评估局部晚期甲状腺癌的可切除性。
- 该量表有潜力帮助临床医生制定局部晚期甲状腺癌的治疗计划。
局限性
- 原文指出需要更大样本量验证以确认量表效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To establish a computed tomography (CT)-based scale to evaluate the resectability of locally advanced thyroid cancer.
METHODS: This twin-centre retrospective study included 95 locally advanced thyroid cancer patients from the 1st centre as the training cohort and 31 patients from the 2nd centre as the testing cohort, who were categorised into the resectable and unresectable groups. Three radiologists scored the CT scans of each patient by evaluating the extension to the recurrent laryngeal nerve (RLN), trachea, oesophagus, artery, vein, soft tissue, and larynx. A 14-score scale (including all comprised structures) and a 12-score scale (excluding larynx) were developed. Receiver-operating characteristic (ROC) analysis was used to evaluate the performance of the scales. Stratified fivefold cross-validation and external verification were used to validate the scale.
RESULTS: In the training cohort, compromised RLN (p < 0.001), trachea (p = 0.001), oesophagus (p = 0.002), artery (p < 0.001), vein (p = 0.005), and soft tissue (p < 0.001) were predictors for unresectability, while compromised larynx (p = 0.283) was not. The 12-score scale (AUC = 0.882, 95%CI: 0.812-0.952) was not inferior to the 14-score scale (AUC = 0.891, 95%CI: 0.823-0.960). In subgroup analysis, the AUCs of the 12-score scale were 0.826 for treatment-naïve patients and 0.976 for patients with prior surgery. The 12-score scale was further validated with a fivefold cross-validation analysis, with an overall accuracy of 78.9-89.4%. Finally, external validation using the testing cohort showed an AUC of 0.875.
CONCLUSIONS: The researchers built a CT-based 12-score scale to evaluate the resectability of locally advanced thyroid cancer. Validation with a larger sample size is required to confirm the efficacy of the scale.
CLINICAL RELEVANCE STATEMENT: This 12-score CT scale would help clinicians evaluate the resectability of locally advanced thyroid cancer.
KEY POINTS: • The researchers built a 12-score CT scale (including recurrent laryngeal nerve, trachea, oesophagus, artery, vein, and soft tissue) to evaluate the resectability of locally advanced thyroid cancer. • This scale has the potential to help clinicians make treatment plans for locally advanced thyroid cancer.
引用
- Huang NS, Li Q, Gao XY, et al. Using a CT-based scale to evaluate disease extension and the resectability of locally advanced thyroid cancer. Eur Radiol. 2023. PMID: 37439940. doi:10.1007/s00330-023-09799-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。